Show simple item record

dc.contributor.authorKollár, A
dc.contributor.authorJones, RL
dc.contributor.authorStacchiotti, S
dc.contributor.authorGelderblom, H
dc.contributor.authorGuida, M
dc.contributor.authorGrignani, G
dc.contributor.authorSteeghs, N
dc.contributor.authorSafwat, A
dc.contributor.authorKatz, D
dc.contributor.authorDuffaud, F
dc.contributor.authorSleijfer, S
dc.contributor.authorvan der Graaf, WT
dc.contributor.authorTouati, N
dc.contributor.authorLitière, S
dc.contributor.authorMarreaud, S
dc.contributor.authorGronchi, A
dc.contributor.authorKasper, B
dc.date.accessioned2016-09-28T14:38:33Z
dc.date.issued2017-01
dc.identifier.citationActa oncologica (Stockholm, Sweden), 2017, 56 (1), pp. 88 - 92
dc.identifier.issn0284-186X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/152
dc.identifier.eissn1651-226X
dc.identifier.doi10.1080/0284186x.2016.1234068
dc.description.abstractBackground Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy including anthracyclines. Data on the efficacy in vascular sarcomas are limited. The main objective of this study was to investigate the activity of pazopanib in vascular sarcomas.Patients and methods A retrospective study of patients with advanced vascular sarcomas, including angiosarcoma (AS), epithelioid hemangioendothelioma (HE) and intimal sarcoma (IS) treated with pazopanib in real life practice at EORTC centers as well as patients treated within the EORTC phase II and III clinical trials (62043/62072) was performed. Patient and tumor characteristics were collected. Response was assessed according to RECIST 1.1. and survival analysis was performed.Results Fifty-two patients were identified, 40 (76.9%), 10 (19.2%) and two (3.8%) with AS, HE and IS, respectively. The response rate was eight (20%), two (20%) and two (100%) in the AS, HE and IS subtypes, respectively. There was no significant difference in response rate between cutaneous and non-cutaneous AS and similarly between radiation-associated and non-radiation-associated AS. Median progression-free survival (PFS) and median overall survival (OS; from commencing pazopanib) were three months (95% CI 2.1-4.4) and 9.9 months (95% CI 6.5-11.3) in AS, respectively.Conclusion The activity of pazopanib in AS is comparable to its reported activity in other STS subtypes. In this study, the activity of pazopanib was similar in cutaneous/non-cutaneous and in radiation/non-radiation-associated AS. In addition, pazopanib showed promising activity in HE and IS, worthy of further evaluation.
dc.formatPrint-Electronic
dc.format.extent88 - 92
dc.languageeng
dc.language.isoeng
dc.subjectTunica Intima
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectHemangiosarcoma
dc.subjectHemangioendothelioma, Epithelioid
dc.subjectLymphatic Metastasis
dc.subjectSulfonamides
dc.subjectPyrimidines
dc.subjectAngiogenesis Inhibitors
dc.subjectNeoplasm Staging
dc.subjectPrognosis
dc.subjectSurvival Rate
dc.subjectRetrospective Studies
dc.subjectFollow-Up Studies
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.titlePazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
dc.typeJournal Article
dcterms.dateAccepted2016-09-05
rioxxterms.versionofrecord10.1080/0284186x.2016.1234068
rioxxterms.licenseref.startdate2017-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfActa oncologica (Stockholm, Sweden)
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume56
pubs.embargo.termsNot known
icr.researchteamClinical and Translational Sarcomaen_US
icr.researchteamSarcoma Clinical Trials (R Jones)en_US
dc.contributor.icrauthorvan der Graaf, Wilhelmina
dc.contributor.icrauthorJones, Robin
dc.contributor.icrauthorMarsden,


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record